Shorts in the past here have typically not hit the bid, mostly just put up big offers when stock runs on news. I think we are seeing natural selling from those twitter traders and shift into stronger, longer term hands. We shall see.
There are many micro cap bio's that have same or much larger market cap that havent even done human testing yet, let alone a P1. Each one trades on its own hype.
APHB is a good example. About a 50 mil market cap an no clinical trials yet. You can find many others.
A company like rgrx which is going into phase 3 and has No expenses for trial and shares big time with a JV in a very big indication should be much higher. Investors have been disappointed by managements failures in the past, so its a show me stock for many potential investors. But, things are changing here. For those that recognize that, potential returns could be great.
Its an interesting proposition; the manipulation of stock price higher to get warrants in the money. In this recent bio rally this last year, i have seen many small bio's run past warrant price and get some much needed cash. RGRX would love to see that happen. They havent got a funding over 50 cents in some time.
Its hard to say how many shares it might take. It would all depend on if the short showed up again. Without the supply from the short, I would think the million shares might do it. Much more if the mm started his nonsense again. And if short needed to cover on news........?
In real money, a couple 100 thousand dollars of buying to get millions in the bank for rgrx? Its been known to happen. Regardless of warrants, short has disappeared and slow uptick continues on some real accumulation.
Sentiment: Strong Buy
Are they wasting our money on another exhibition? They have been doing these things for years and shareholders never get any return. These knuckleheads should be banned from spending any more money on these things.
Its insane; doing the same thing over and over again and expecting a different result. Ma should be FIRED. Or jailed with his buddies Castle and Leiberman. What a bunch of hucksters. FUMA
Sno, your self promotion is boundless. As always and as your history has shown, you are clueless and new investors here should mostly ignore your conclusions.
Sno, you dont know when and what the next positive news will be. Your statements as fact on timing of trials are just poor speculations.
Your lack of urgency in buying shares is a mistake; again. Recent actions suggests shares are (will) move higher into next near term event as word is getting out. You cant wait to buy size on news, stock is just too illiquid. And you discount warrants but real news could have stock blow by 50 cents very easily. Will it come by May? Just maybe. But, real play is the equity for the year......1++++++++++++++++
The simple unfortunate truth about this company and management is that they do not care for shareholders and any imput they may have. And they want to keep the company as far under the radar as possible, so as to keep their incompetence and greed "unnoticed."(Dempsey payoff) The company and its cash cow gehc exists for one reason; to pay extreme salaries and stock options to Ma & co for as long as possible, as they do little to nothing.....great job if you can get it.
An endpoint on inflamation reduction after eye surgery was missed by Ocul and 100's of millions of dollars cut on market cap. They hit the pain endpoint(although not for shareholders). With all its wound healing properties and abstracts on positive effect on inflamation and super saftey profile in the eye with TB4, Fink should get on the phone and call ocul's ceo and suggest they take a look at tb4 in combo trial. Lots of drugs appoved in combo. Seems like great potential here. Mixing a steriod with TB4? Why not.
Of course they could have failed. But, proper endpoints run by a professional company might have changed the course of eecp therapy.
All shareholders would have been all in on a trial. We all were advocates of eecp and invested in eecp. We did not invest in what has now been turned into an Unsuccessful, China based company marketing medical devices with dubious merits............NO demand. They dont even have FDA approval.
Every biotech company eventually has a binary event with a trial. Its the nature of investing in this area.
That is just the way it is. If you wont commit to that, you should find another business. But reseller thinks companies like biogen, Merck......are clowns for doing them. What a great little world resller must live in, all drugs and devices get approved because;or better yet, dont really have to be done at all. Cardiologist should just except whatever vaso says about eecp. Yeah, thats it.
Reseller the past is done. No one believes in Ma at this point. That is very clear by reaction to last years profit. He should go. By any fair measure, he does not deserve his pay package.
Man, you sure got alot time on your hands to go back a look through every post. I hope vaso is paying you overtime to find my comments which really just amount to hopeful hype; talking my book as it were. Funny, how it just amounts to another democrate stepping on his #$%$ at our expense.
Reseller, the morality of results is all that mattters to a public company. The best of intentions are as worthlessas yourposts. Rios and the agenda set by Ma failed. What dont you get? The trials may well have hit an endpoint; we will never know. Since you are being paid for your time, go back and you will find many post of mine advocating a serious trial as well as a constant theme of staying away from China before any deal there. China is a worthless pit which Ma will never be able to navigate.
Your defense of Ma's decision to abandon any trial and pay Rios is ridiculous. It failed. It cost many shares. It has contributed to share price decline. You must be best buds with that drunk Castle who voted pay raises to Ma. I am sure he wanted to reward Ma for picking Rios. The failure of same really doesnt matter to vaso, as shareholders will just pick up the tab.
(Or you might even be that big dope Castle himself..........)
ran into walls that you have no clue about.
A statement which again points to you being an employee of this dysfunctional company. No one praised Rios, we were all hopeful and believed in Ma at the time. So, huge up front payment and massive backend must have been for a reason? But, was a huge waste of money and the start of the decline in confidence in Ma. This failure was quickly followed by horrible China acquisition and grossly false hype by Ma of the India market. And bailout of Dempsey while no buyback now for real shareholders.
What is your point reseller. Nothing you say is useful or real as it applies to shareprice today. You defend Rios? Facts are he failed; no one cares why right now.
And trials were the way to go. Way back when gehc was first done, Ma made a choice to go to his homeland and buy a worthless Chinese company BEFORE their was any demand for those devices/products. Did this guy even take busness 101? What a friggin dope. He should have started a real trial then, 3 years ago. We could have taken all the gehc money from those 3 years and completed trial. We will never know the result, because we have taken a different route. And the result so far, and 3 years is long enough in the business world to say that his way has been a disaster for shareholders. The share price tells the story, not you and your endless false hype.
Why dont you get a real job with a real company reseller? You work with vaso has been about as productive as Ma's.FUMA
Maybe they should have done a combo with TB4 for inflamation reduction. Market is begging for any new eye drug to meet endpoint. TB4 and dry eye will be a huge winner.
Ocular Therapeutix Inc says its lead eye drug failed to meet one of the main goals in a second late-stage study.
The drug, OTX-DP, was effective in reducing pain in patients who had cataract surgery, but failed to reduce the inflammation in the eyes, the company said.
Whose opinion/recommendations have made more moeny for investors on this board? The Donk or Bocamp?
I say they have needed patents, you disagree ad nausuam. Based on track record, who has more credibility?
What you say Donkless?
We know you are a lackey for the shorts. And we know you are paid pennies for your posts. Good for you. YOu dont seem to understand that eye indications are covered under the wound healing patents.
Now, what are your investment recommendations? Do you have any? Something actionable? This is an investment board.
Hey mia, constructive criticism and all your comments are always appreciated.
The truth of this mostly worthless board is that I am the only one who has given any actionable, profitable recommendations.
I pounded that table to buy with both fists at the 10 cent lows, averaging down. I gave all a strong buy in sngx when Kirk took a stake. I gave board the exact timing and recommendation on the ZIop play right before the deal MD Anderson alliance. And SCLN.........huge winner. Mia, you dont have a life so you can fact check.
Mia, donk are just two worthless voyeurs who never participate in the game, but love to play act, like they know something the rest of us dont. Real message board experts.............lol
Both of you posers should let us all in on your investment recommendations. After all, this is an investment forum. I will be waiting for these 2 experts to share their boundless knowlege with all of us.
And Mia, I make no bones about talking my book. If you ever had one, you might understand.
Reseller, you a such the idiot. Again, another reason it is clear you must be on the vaso payroll. You say M&A is the best way, but history says Ma has NEVER done one that benefited shareholders. The last one that Ma lied about and said was accretive 3 years ago was done when stock was over 30 cents. Have you ever seen an accretive acquisition destroy so much shareholder value? By defintion, that is NOT possible.
You admit to poor "handling"(never heard a lie explained that way-very creative) but say carry on.
MA needs to show that the china acquisition is improving equipment sales and break out #'s on all products. Give us some transparency and results and shareholders will support future acquisitions.
Cant believe those few who know the story here, and have a higher cost basis, are content to sit on their hands and do nothing. No wonder the retail investor never makes any money.
RGRX is a completely different animal then it was. even from just last year.
-Trials about to start which can be finished quickly
-BK off the table and enough cash to see these trials through as expenses are absorbed by China and korean companies. And great JV agreement lets rgrx share in profits.
-New(updated) coverage any time now.
-Short trading pattern change
-New hire close to deals on heart and neuro
-Deep pocketed Korean company fully committed to rgrx and supported by their government.
-NO patent concerns. Both companies did full DD on this and are satisfied that wound healing patents cover all eye applications.
Its a difficult thing to acquire any size in this illiquid stock when news hits. Right now, slow accumulation on the bid taking as much stock as possible without pushing stock much higher. This is a combination of short covering and new "smart" investors.
A year form now........1+++++++